Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Wedbush Reiterates Outperform on Elevation Oncology, Maintains $4 Price Target

Wedbush analyst Robert Driscoll reiterates Elevation Oncology (NASDAQ:ELEV) with a Outperform and maintains $4 price target.
byBenzinga Newsdesk
March 10, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Wedbush analyst Robert Driscoll reiterates Elevation Oncology (NASDAQ:ELEV) with a Outperform and maintains $4 price target.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts